A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function

Clinical trial NCT06397872 · COMPLETED

Trial details

NCT number: NCT06397872
Sponsor: Madrigal Pharmaceuticals, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Renal Impairment

Start date: 2024-03-06
Primary completion: 2024-09-16
Enrollment: 28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.